Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

lt in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214. '/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and MELBOURNE, Australia , ... Nexvet Biopharma today announced the appointments of Dr. ... McCracken D.V.M ., M.S., to its Board of Directors. ... Medical Affairs Finance at Genentech and Chief Financial Officer ... served as Vice President and Global Head of Business ...
(Date:9/18/2014)... JOLLA, Calif. , Sept. 18, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery ... today it has initiated its ATHENA natural history ... a life-threatening genetic kidney disease with no approved ... the natural decline of renal function markers such ...
(Date:9/18/2014)... days before the government of Sierra Leone ... Ebola, World Vision will begin a massive delivery of 200 ... McKesson, the largest healthcare services company in ... Medical-Surgical donated four million pairs of latex gloves – enough ... needs for the next five months* – to ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4
... N.C., Feb. 10, 2011 For the biopharmaceutical ... importance - and difficulty - of interacting with ... restrictions have created both opportunities and challenges for ... control. To help marketing teams in ...
... 3-V Biosciences, Inc. announced today Stephen R. Brady has ...   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "Steve,s contributions have been pivotal ... 3-V," said Merdad V. Parsey, MD, PhD, 3-V,s Chief Executive ... continue to build the 3-V team and advance the company,s ...
Cached Medicine Technology:Innovations in Patient-Focused Initiatives to Improve Outcomes 23-V Biosciences Promotes Stephen R. Brady to Chief Business Officer 2
(Date:9/18/2014)... CRDF Global released today its ... edition – rich with videos, images and interactive ... Global empowers scientists and innovators around the world. ... foundation and individual supporters, CRDF Global reaches across ... training and entrepreneurship. , The Annual Report highlights ...
(Date:9/18/2014)... 18, 2014 Phela Health and Wellness ... HABIT™ Program in South Africa. HABIT™ is a ... and distributed in South Africa by Bestflex. , Phela ... which has been tailored to address issues that are ... behavior modification and chronic disease prevention. This solution combines ...
(Date:9/18/2014)... 2014) A new expert panel report, Improving ... the Council of Canadian Academies, addresses the importance ... Each year about half of Canada,s seven million ... of this prescribing is done off-label (i.e. the ... health risks., Children have historically been excluded in ...
(Date:9/18/2014)... Dr. Andrea Basile, MD, one of the most ... at Basile Plastic Surgery to include Coolsculpting. This non-invasive technique ... in the world for the removal of fat because of ... Dr. Basile, Coolsculpting will greatly benefit those patients with body ... procedure. He also said this procedure is ideal for people ...
(Date:9/18/2014)... 18, 2014 The new BuildClean™ ... to contractors and homeowners alike as it eliminates ... the home, causes potential health issues, and makes ... the BuildClean system allows contractors to virtually eliminate ... other standard remodeling tasks. , BuildClean removes up ...
Breaking Medicine News(10 mins):Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Improving medicines for children in Canada 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4
... Research Group is,an exciting newcomer in the field ... information service established to,provide the general public with ... choose for a variety of medical problems resulting ... the website will be,obtained through an online survey ...
... of the,Board and Chief Executive Officer, A.G. Lafley, addressed ... at its annual meeting today. Lafley,said, "P&G is a ... long term,-- consistently, reliably and sustainably." Growth in ... fiscal 2007. P&G increased,net sales by 12 percent to ...
... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
... Nutrition,(OTC Bulletin Board: NNTN) http://www.interactivenutrition.com will ... 2007 at,11:00 a.m. Eastern time. U.S. and Canadian ... 800-750-4065 and International Shareholders may dial in at,404-920- ... 767872#. Executives,from Natural Nutrition will be available for ...
... Exchange Symbol: AKL, MONTREAL, Oct. 9 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation, pain ... 2007, its issued and outstanding common shares will ... common share for every seven (7),pre-consolidation common shares. ...
Cached Medicine News:Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Natural Nutrition to Hold International Shareholder Conference Call Thursday, October 11, 2007 at 11:00 a.m. Eastern Time 2Health News:Akela Pharma Inc. Completes Share Consolidation 2
BioScrew® Bio-Absorbable Interference Screws and Delivery System Clinically equivalent to metal interference screws....
... Interference Screws. Optimal screw ... graft selection options. Robust ... deformation, and chamfered screw ... atraumatic tissue fixation. Features ...
Cannulated Interference Screws...
... on the TrueView II design, a new ... for small joint arthroscopy is available. The ... very durable thanks to Olympus advanced fibre ... class means bright images, brilliant colour reproduction, ...
Medicine Products: